Taysha Gene Therapies reports this morning with short sellers sitting on a 16.5% short interest position — one of the larger bets against a clinical-stage biotech in the gene therapy space — while every analyst covering the stock carries a buy-equivalent rating and a price target well above last night's close of $6.68.
Short interest is the clearest tension here. Nearly 45.3 million shares are borrowed against the float, a level that has climbed 17% over the past month from roughly 38.7 million to its current reading. That is a meaningful and deliberate accumulation of bearish positioning. Despite that weight, availability in the lending pool remains loose — around 780% relative to short interest — meaning there is no immediate squeeze pressure, and borrow costs have actually eased, falling 12% on the week to 0.5%. Options positioning, far from reinforcing the bearish case, is decidedly call-heavy. The put/call ratio of 0.17 is just modestly above its 20-day average of 0.14, nowhere near defensive territory. The stock itself has added 7.7% on the week and 5.4% over the past month, trading counter to the short buildup.
The bull and bear camps are not fighting about the same thing. Bulls point to TSHA-102's 100% response rate in initial Rett syndrome patients, the absence of any approved disease-modifying treatment for the condition, and a near-unanimous analyst consensus that nine buy ratings and a mean price target of $13.25 — roughly double the current price — quantifies the upside. Goldman Sachs raised its target to $13 on July 21, and Baird lifted to $15 at end of June, both while maintaining positive ratings. Bears focus on safety: the revision of baseline scoring in trial data and reports of sensory neuropathy in TSHA-102 patients raise questions about what the pivotal readout will show. The deeply negative earnings picture — EV/EBITDA of -9.4x and a price-to-earnings multiple of -14.6x reflecting the cash-burn reality of a pre-revenue company — is not itself the concern, but the need for future financing rounds is.
Institutional ownership adds another layer. Goldman Sachs Asset Management nearly tripled its stake in Q2, adding close to 8.9 million shares. BlackRock added 2.3 million. Vanguard Capital Management initiated a fresh position of 11.8 million shares as of June 30. These are not passive index flows — they are active fund decisions that run squarely against the short sellers' thesis. The most recent insider activity cuts the other way: the company's President sold 200,000 shares on July 10 at $6.24, the second such 200,000-share sale of the year.
The print is therefore a test of whether the clinical story justifies the 17% monthly short interest buildup, or whether safety data and the path to pivotal trials can silence the sceptics and close a gap between a $6.68 stock price and a Street consensus target that implies nearly 100% upside.
See the live data behind this article on ORTEX.
Open TSHA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
